SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)
Funding Opportunity RFA-ES-19-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to further the development of Advanced Technology Training (ATT) products for: the health and safety training of hazardous materials (HAZMAT) workers; waste treatment personnel; skilled support personnel associated with an emergency/disaster; emergency responders in biosafety response, infectious disease training and cleanup; emergency responders in disasters and resiliency traini...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 30, 2019 Category: Research Source Type: funding
Notice of Budget Change in RFA-AI-19-028 Emerging Infectious Diseases Research Centers (U01 Clinical Trial Not Allowed)
Notice NOT-AI-19-056 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 4, 2019 Category: Research Source Type: funding
U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (Infectious Diseases) (R01 Clinical Trial Optional)
Funding Opportunity RFA-AI-19-024 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to continue the U.S.-South Africa Program for Collaborative Biomedical Research into Phase 2. Research areas supported under this program include: tuberculosis; sexually transmitted infections; parasitic infections; arboviruses and emerging/re-emerging viral pathogens; and vector biology and control. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 15, 2019 Category: Research Source Type: funding
U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (Infectious Diseases) (U01 Clinical Trial Optional)
Funding Opportunity RFA-AI-19-025 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to continue the U.S.-South Africa Program for Collaborative Biomedical Research into Phase 2. Research areas supported under this program include: tuberculosis; sexually transmitted infections; parasitic infections; arboviruses and emerging/re-emerging viral pathogens; and vector biology and control. This opportunity is specifically designed to promote partnerships between eligible NIH Intramural Research Program (IRP) investigators (e.g. those conducting research within the labor...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 15, 2019 Category: Research Source Type: funding
Emerging Infectious Diseases Research Centers (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-19-028 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to establish a coordinated network of Emerging Infectious Disease Research Centers (EIDRCs) in regions around the globe where emerging and re-emerging infectious disease outbreaks are likely to occur. Multidisciplinary teams of investigators will conduct pathogen/host surveillance, study pathogen transmission, pathogenesis and immunologic responses in the host, and will develop reagents and diagnostic assays for improved detection for important emerging pathogens and their vectors....
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 5, 2019 Category: Research Source Type: funding
Emerging Infectious Diseases Research Centers - Coordination Center (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-19-029 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for an Emerging Infectious Diseases Research Centers Coordination Center (EIDRC CC) for the Emerging Infectious Diseases Research Centers (EIDRC). The EIDRC CC will oversee and coordinate select aspects of each EIDRCs research project(s) involving data management, sample collection and storage, sharing of reagents, diagnostics, and resources, and will facilitate collaboration between the newly awarded EIDRCs, and other USG and international agencies, as appr...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 4, 2019 Category: Research Source Type: funding
U.S.-Brazil Collaborative Biomedical Research Program (R01 Clinical Trial Optional)
Funding Opportunity RFA-AI-18-054 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to promote collaborative biomedical research between the United States and Brazil under the U.S.-Brazil Biomedical Collaborative Research Program. Research areas supported under this program include allergy, immunology, and infectious diseases, including HIV/AIDS and its co-morbidities; cancer; mother-to-child transmission of HIV and other congenital infections, early infant diagnosis and treatment; HIV/AIDS in relation to mental health; and neurological disorders and stroke. (Sour...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 4, 2018 Category: Research Source Type: funding
Secondary Analysis of Existing Datasets for Advancing Infectious Disease Research (R21 Clinical Trial Not Allowed)
Funding Opportunity PA-19-068 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support projects that utilize open-access data, alone or in combination with other datasets, to address knowledge gaps in basic and clinical infectious diseases. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 13, 2018 Category: Research Source Type: funding
Processing and Presentation of Non-Conventional MHC Ligands (R21 Clinical Trial Not Allowed)
Funding Opportunity PA-19-066 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to determine antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands and to determine the contribution of these unique antigenic ligands to protective immune responses against infectious disease pathogens and/or vaccines; pathogen-associated immune pathogenesis; and/or limit progression or induction of immune-mediated diseases. These studies may facilitate the development of novel tools and reagents to advance design of immune...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 13, 2018 Category: Research Source Type: funding
Global Noncommunicable Diseases and Injury Across the Lifespan: Exploratory Research (R21 Clinical Trials Optional)
Funding Opportunity PAR-19-059 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports planning, design and initial pilots for locally relevant and catalytic research on non-communicable diseases (NCDs) or injury in low and middle-income countries (LMICs). Research addressing multiple NCDs and their risk factors and research addressing NCDs as comorbidities for/with infectious diseases including HIV/AIDS is encouraged. Scientists in the United States (U.S.) or upper middle income countries (UMICs) are eligible to partner with scientists in LMIC institutions. Income categories us...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 7, 2018 Category: Research Source Type: funding
Request for Information (RFI): Soliciting Input on the National Institutes of Allergy and Infectious Diseases (NIAID) New Innovator Awards (DP2 Clinical Trials Optional)
Notice NOT-AI-19-013 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 5, 2018 Category: Research Source Type: funding
What Contributes to the Success of Early Career Scientists? – A NIAID Look
At NIH, we are heavily invested in our workforce and in understanding the barriers they face. What characteristics do they share? How do they compete in the current hypercompetitive environment? When do they stop applying to NIH (drop out), even after receiving their first award?
Staff from the National Institute of Allergy and Infectious Diseases (NIAID) delve into these questions in a paper published recently in PLOS ONE , whose findings I’d like to highlight today. Here, Drs. Patricia Haggerty and Matthew Fenton looked at factors that may contribute to the success of early-career investigators and if these factors aff...
Source: NIH Extramural Nexus - October 31, 2018 Category: Research Authors: Mike Lauer Tags: blog Open Mike Uncategorized biomedical research workforce Biomedical Workforce Early Stage Investigators Funding data funding rate Source Type: funding
Notice of NIH Participation in the Ecology and Evolution of Infectious Diseases Program
Notice NOT-TW-18-005 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 23, 2018 Category: Research Source Type: funding
Notice of Webinar and FAQs for NIAID Vaccine and Treatment Evaluation Units (UM1 Clinical Trial Required) and Leadership Group for an Infectious Diseases Clinical Research Consortium (IDCRC) (UM1 Clinical Trial Required), RFA-AI-18-046 and RFA-AI-18-047
Notice NOT-AI-19-008 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 18, 2018 Category: Research Source Type: funding
Request for proposal (rfp): bioinformatics resource centers for infectious diseases, rfp-niaid-dmid-nihai201800005
Notice NOT-AI-19-009 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 15, 2018 Category: Research Source Type: funding
